Tag - PSTX

Markets

HCW starts Poseida Therapeutics at buy; PT $15

H.C. Wainwright initiated coverage of Poseida Therapeutics (NASDAQ:PSTX) with a “buy” rating and $15 price target. The stock closed at $5.79 on Jan. 2. Poseida is a clinical-stage biopharmaceutical company focused on...

January 4, 2023

Markets

BTIG halves Poseida Therapeutics PT to $20 from $40

BTIG slashed its price target for Poseida Therapeutics (NASDAQ:PSTX) to $20 from $40 but maintained its “buy” rating after increasing its modeled discount rate to 14% from $12, given current market conditions. The stock...

May 13, 2022

Markets

BTIG starts coverage of six cell therapy and immuno-oncology companies at buy

BTIG initiated coverage on six companies with “buy” ratings that it believes are undervalued players in the cell therapy space, each developing some variation of autologous CAR-Ts, “off-the-shelf” allogeneic CAR-Ts...

May 17, 2021

Markets

WB starts Poseida Therapeutics at OP; fair value estimate $39

William Blair launched coverage of Poseida Therapeutics (NASDAQ:PSTX) with an “outperform” rating and fair value estimate of $39. The stock closed at $12.98 on Aug. 3. “In our view, Poseida’s broad suite of platform...

August 4, 2020

Tag - PSTX

HCW starts Poseida Therapeutics at buy; PT $15

BTIG halves Poseida Therapeutics PT to $20 from $40

BTIG starts coverage of six cell therapy and immuno-oncology companies at buy

WB starts Poseida Therapeutics at OP; fair value estimate $39

General

More